<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923740</url>
  </required_header>
  <id_info>
    <org_study_id>12-397</org_study_id>
    <nct_id>NCT01923740</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)</brief_title>
  <acronym>ABSORB CHINA</acronym>
  <official_title>A Clinical Evaluation of Absorb™ BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V
      Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic
      heart disease caused by up to two de novo native coronary artery lesions in separate
      epicardial vessels.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment Late Loss (LL) - Per Subject Analysis</measure>
    <time_frame>At 1 year</time_frame>
    <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent from post-procedure to 1 year by angiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-segment Late Loss (LL) - Per Lesion Analysis</measure>
    <time_frame>At 1 year</time_frame>
    <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent from post-procedure to 1 year by angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Successful delivery and deployment of the assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final inscaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.
Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Procedural Success</measure>
    <time_frame>At time of procedure up to 7 days in hospital</time_frame>
    <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days). In dual target lesion setting, both lesions must meet clinical procedure success criteria to have a patient level procedure success.
Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population (PTE) analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 37days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 208 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 298 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>0 to 393 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 208 days</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 298 days</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>0 to 393 days</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Myocardial Infarction</measure>
    <time_frame>2 years</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>3 years</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>4 years</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
    <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 208 days</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 298 days</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 393 days</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>4 years</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>5 years</time_frame>
    <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 208 days</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 298 days</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 393 days</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>4 years</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>5 years</time_frame>
    <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>0 to 37days</time_frame>
    <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>0 to 208 days</time_frame>
    <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>0 to 298 Days</time_frame>
    <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>0 to 393 Days</time_frame>
    <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>2 years</time_frame>
    <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>3 years</time_frame>
    <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>4 years</time_frame>
    <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Coronary Revascularization (PCI and CABG)</measure>
    <time_frame>5 years</time_frame>
    <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death/All MI</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death/All MI</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death/All MI</measure>
    <time_frame>0 to 208 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death/All MI</measure>
    <time_frame>0 to 298 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Death/All MI</measure>
    <time_frame>0 to 393 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death/All MI</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death/All MI</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death/All MI</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death/All MI</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI</measure>
    <time_frame>0 to 208 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI</measure>
    <time_frame>0 to 298 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI</measure>
    <time_frame>0 to 393 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 208 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 298 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 393 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>0 to 208 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>0 to 298 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>0 to 393 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>0 to 208 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>0 to 298 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>0 to 393 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>0 to 208 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>0 to 298 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>0 to 393 days</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Stent/Scaffold Thrombosis (Per Academic Research Consortium (ARC) Definition)</measure>
    <time_frame>&lt; or = 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Subacute Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>&gt;1 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>31 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Stent/Scaffold Thrombosis (Per ARC Definition)</measure>
    <time_frame>0 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Segment Minimum Lumen Diameter (MLD)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.
INSEGMENT: Within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Device Minimum Lumen Diameter (MLD)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Minimum Lumen Diameter (MLD)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Minimum Lumen Diameter (MLD)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Segment Percent Diameter Stenosis (%DS)</measure>
    <time_frame>At 1 year</time_frame>
    <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Device Percent Diameter Stenosis (%DS)</measure>
    <time_frame>At 1 year</time_frame>
    <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Percent Diameter Stenosis (%DS)</measure>
    <time_frame>At 1 year</time_frame>
    <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Percent Diameter Stenosis (%DS)</measure>
    <time_frame>At 1 year</time_frame>
    <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Segment Angiographic Binary Restenosis (ABR)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%. InSegment is defined as within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Device Angiographic Binary Restenosis (ABR)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Angiographic Binary Restenosis (ABR)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Angiographic Binary Restenosis (ABR)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Segment Late Loss (LL)</measure>
    <time_frame>At 1 year</time_frame>
    <description>In-segment Late Loss is calculated as (in-segment MLD post-procedure) - (in-segment MLD at followup).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Device Late Loss (LL)</measure>
    <time_frame>At 1 year</time_frame>
    <description>In-device late loss is calculated as (in-device MLD post-procedure) - (in-device MLD at followup).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal Late Loss (LL)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Proximal Late Loss: Proximal MLD post procedure - Proximal MLD at followup.
Proximal is defined as within 5 mm of healthy tissue proximal to the device placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal Late Loss (LL)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Distal Late Loss calculated as Distal MLD post procedure - Distal MLD at followup.
Distal is defined as within 5 mm of healthy tissue distal to the device placement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Absorb BVS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE V EECSS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V EECSS</intervention_name>
    <description>Subjects receiving XIENCE V</description>
    <arm_group_label>XIENCE V EECSS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb BVS System</intervention_name>
    <description>Subjects receiving Absorb BVS System</description>
    <arm_group_label>Absorb BVS System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 18 years of age at the time of signing the informed consent
             form.

          2. Subject or a legally authorized representative must provide written Informed Consent
             prior to any study related procedure.

          3. Subject must have evidence of myocardial ischemia (e.g., stable angina, unstable
             angina, post-infarct angina or silent ischemia) suitable for elective percutaneous
             coronary intervention (PCI). Subjects with stable angina or silent ischemia and &lt; 70%
             diameter stenosis must have objective sign of ischemia as determined by one of the
             following, echocardiogram, nuclear scan, ambulatory ECG or stress ECG. In the absence
             of noninvasive ischemia, fractional flow reserve (FFR) must be done and indicative of
             ischemia.

          4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery.

          5. Female subject of childbearing potential does not plan pregnancy for up to 1 year
             following the index procedure. For a female subject of childbearing potential, a
             pregnancy test must be performed with negative results known within 14 days (≤14 days)
             prior to the index procedure per site standard test.

          6. Female subject is not breast-feeding at the time of the screening visit and will not
             be breast-feeding for up to 1 year following the index procedure.

          7. Subject agrees to not participate in any other investigational clinical studies for a
             period of 1 year following the index procedure.

        Exclusion Criteria:

          1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or P2Y12
             inhibitor is planned within 12 months after the index procedure.

          2. Subject has a known hypersensitivity or contraindication to device material (cobalt,
             chromium, nickel, tungsten, acrylic and fluoro polymers) and its degradants
             (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid). Subject has a
             known contrast sensitivity that cannot be adequately pre-medicated.

          3. Subject has a known allergic reaction, hypersensitivity or contraindication to:

               1. Aspirin; or

               2. All P2Y12 inhibitors (including clopidogrel and ticlopidine, and prasugrel and
                  ticagrelor when they become available); or

               3. Heparin and bivalirudin.

          4. Subject had an acute myocardial infarction (AMI) within 7 days of the index procedure
             and both creatine kinase (CK) and creatine kinase myocardial-band isoenzyme (CK-MB)
             have not returned to within normal limits at the time of index procedure.

          5. Subject is currently experiencing clinical symptoms consistent with new onset AMI,
             such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.

          6. Subject has a cardiac arrhythmia as identified at the time of screening which at least
             one of the following criteria is met:

               1. Subject requires coumadin or any other agent for chronic oral anticoagulation.

               2. Subject likely to become hemodynamically unstable due to their arrhythmia.

               3. Subject has poor survival prognosis due to their arrhythmia.

          7. Subject has a known left ventricular ejection fraction (LVEF) &lt; 30% assessed by any
             quantitative method. LVEF may be obtained within 6 months prior to the procedure for
             subjects with stable coronary artery disease (CAD). For subjects presenting with acute
             coronary syndrome (ACS), LVEF must be assessed during the index hospitalization (which
             may include during the index procedure by contrast left ventriculography) but prior to
             randomization in order to confirm the subject's eligibility.

          8. Subject has received CABG at any time in the past.

          9. Subject has undergone prior PCI within the target vessel during the last 12 months or
             undergone prior PCI within the non-target vessel within 30 days before the index
             procedure.

         10. Subject requires future staged PCI either in target or non-target vessels.

         11. Subject has received any solid organ transplants or is on a waiting list for any solid
             organ transplants.

         12. At the time of screening, the subject has a malignancy that is not in remission.

         13. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
             autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus,
             etc.). Note: corticosteroids are not included as immunosuppressant therapy.

         14. Subject has previously received or is scheduled to receive radiotherapy to coronary
             artery (vascular brachytherapy), or chest/mediastinum.

         15. Subject is receiving or will receive chronic anticoagulation therapy (e.g., coumadin
             or any other anticoagulation agents).

         16. Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3.

         17. Subject has a known or documented hepatic disorder as defined as cirrhosis or
             Child-Pugh ≥ Class B.

         18. Subject has known renal insufficiency as defined as an estimated glomerular filtration
             rate (eGFR) &lt; 30 ml/min/1.73m2 or dialysis at the time of screening.

         19. Subject is high risk of bleeding; has a history of bleeding diathesis or coagulopathy;
             has had a significant gastro-intestinal or significant urinary bleed within the past
             six months; will refuse blood transfusions.

         20. Subject has had a cerebrovascular accident or transient ischemic neurological attack
             (TIA) within the past six months or any prior intracranial bleed, any permanent
             neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous
             malformation, etc.).

         21. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion. Note: femoral arterial disease does not exclude the subject if radial or
             brachial access can be used.

         22. Subject has life expectancy &lt; 2 years for any non-cardiac cause or cardiac cause.

         23. Subject is in the opinion of the Investigator or designee, unable to comply with the
             requirements of the study protocol or is unsuitable for the study for any reason.

         24. Subject is currently participating in another clinical trial that has not yet
             completed its primary endpoint or protocol-required medications or invasive
             procedures.

        Angiographic Inclusion Criteria

        Assessment of angiographic eligibility is per visual assessment by an investigator both for
        qualitative and quantitative variables. On-line QCA is recommended to be used for
        appropriately sizing of the vessel. If on-line QCA cannot be used, visual estimation is
        required.

          1. One or two de novo target lesions:

               1. If there is one target lesion, a second non-target lesion may be treated but the
                  non-target lesion must be present in a different epicardial vessel, and must be
                  treated first with a successful, uncomplicated result prior to randomization of
                  the target lesion.

               2. If two target lesions are present, they must be present in different epicardial
                  vessels and both satisfy the angiographic eligibility criteria.

               3. The definition of epicardial vessels means the left anterior descending artery
                  (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and
                  their branches. Thus, for example, the subject must not have lesions requiring
                  treatment in both the LAD and a diagonal branch.

          2. Target lesion must be located in a native coronary artery with a visually estimated or
             quantitatively assessed %DS of ≥ 50% and &lt; 100% with a thrombolysis in myocardial
             infarction (TIMI) flow of ≥ 1 and one of the following: stenosis ≥ 70%, an abnormal
             functional test (e.g., fractional flow reserve, stress test), unstable angina or
             post-infarct angina.

          3. Target lesion must have a Dmax (by on-line QCA) or reference vessel diameter (RVD) (by
             visual estimation) ≥ 2.50 mm and ≤ 3.75 mm (on-line QCA assessment is recommended).

          4. Target lesion must have a lesion length ≤ 24 mm based on either visual estimation or
             on-line QCA.

        Angiographic Exclusion Criteria

        All exclusion criteria apply to the target lesion(s) or target vessel(s). All exclusion
        criteria are based on visual estimation.

          1. Target lesion is located in left main.

          2. Aorto-ostial RCA target lesion (within 3 mm of the ostium).

          3. Target lesion located within 3 mm of the origin of the LAD or LCX.

          4. Lesion involving a bifurcation with a:

               1. Side branch ≥ 2 mm in diameter, or

               2. Side branch with diameter stenosis ≥ 50%, or

               3. Side branch requiring protection guide wire, or

               4. Side branch requiring pre-dilatation

          5. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or
             XIENCE V, including:

               1. Extreme angulation (≥ 90°) proximal to or within the target lesion

               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion

               3. Moderate or heavy calcification proximal to or within the target lesion

          6. Target lesion or target vessel involves a myocardial bridge.

          7. Target vessel contains thrombus as indicated in the angiographic images.

          8. Target vessel has been previously treated with a stent at any time prior to the index
             procedure such that the Absorb BVS or XIENCE V would need to cross the stent to reach
             the target lesion.

          9. Target vessel has been previously treated with a stent and the target lesion is within
             5 mm proximal to a previously treated lesion.

         10. Target lesion which prevents complete balloon pre-dilatation, defined as full balloon
             expansion with the following outcomes:

               1. Residual %DS is &lt; 40% (per visual estimation), ≤ 20% is strongly recommended.

               2. TIMI Grade-3 flow (per visual estimation).

               3. No angiographic complications (e.g. distal embolization, side branch closure).

               4. No dissections National Heart, Lung, and Blood Institute (NHLBI) grade D-F.

               5. No chest pain lasting &gt; 5 minutes.

               6. No ST depression or elevation lasting &gt; 5 minutes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao Runlin, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2013</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <results_first_submitted>January 16, 2018</results_first_submitted>
  <results_first_submitted_qc>January 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2018</results_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Absorb™ BVS</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>BVS</keyword>
  <keyword>Bioresorbable</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Artery Endothelial Responsiveness</keyword>
  <keyword>Coronary artery restenosis</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <keyword>Coronary scaffold</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Stent thrombosis</keyword>
  <keyword>Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrollment of the ABSORB China RCT began on July 31, 2013 &amp; completed on March 13, 2014 with the first subject randomized on 2 August 2013. A total of 480 subjects (Intent-to-treat (ITT) population) were randomized (Absorb BVS:241&amp;XIENCE:239) at 24 clinical sites in mainland China. The last subject completed the 1 year follow-up on May 7, 2016.</recruitment_details>
      <pre_assignment_details>Of the 480 ITT subjects, 21 were excluded from the PTE population due to pre-specified protocol/treatment deviations or due to subject withdrawal prior to any study device attempts during the index procedure. Thus, of the 459 subjects in the PTE population, 227 were randomized to the Absorb BVS arm and 232 were randomized to the XIENCE V arm</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb BVS System</title>
          <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
        </group>
        <group group_id="P2">
          <title>XIENCE V EECSS</title>
          <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>30-day Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227">Per-treatment-evaluable (PTE) population</participants>
                <participants group_id="P2" count="232">Per-treatment-evaluable (PTE) population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>180-day Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>270-day Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1 Year Clinical Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb BVS System</title>
          <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
        </group>
        <group group_id="B2">
          <title>XIENCE V EECSS</title>
          <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="227"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="11.4"/>
                    <measurement group_id="B2" value="57.7" spread="9.6"/>
                    <measurement group_id="B3" value="57.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In-segment Late Loss (LL) - Per Subject Analysis</title>
        <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent from post-procedure to 1 year by angiography.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment Evaluable Population set (PTE). For subjects with more than one target lesion, the average of in-segment late loss was used for analysis. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Late Loss (LL) - Per Subject Analysis</title>
          <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent from post-procedure to 1 year by angiography.</description>
          <population>Per-Treatment Evaluable Population set (PTE). For subjects with more than one target lesion, the average of in-segment late loss was used for analysis. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.38"/>
                    <measurement group_id="O2" value="0.13" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>In-segment Late Loss (LL) - Per Lesion Analysis</title>
        <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent from post-procedure to 1 year by angiography.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment Evaluable Population set (PTE). Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Late Loss (LL) - Per Lesion Analysis</title>
          <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent from post-procedure to 1 year by angiography.</description>
          <population>Per-Treatment Evaluable Population set (PTE). Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.40"/>
                    <measurement group_id="O2" value="0.13" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success</title>
        <description>Successful delivery and deployment of the assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final inscaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.
Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only.</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <population>Intent to treat set (ITT). Four subjects (1 in the Absorb BVS arm and 3 in the XIENCE V arm) were excluded from the data analysis for acute success.
During the index procedure, 5 subjects withdrew consent following randomization and before any device attempts,3 in the Absorb BVS arm and 2 in the XIENCE V arm were excluded from all data analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success</title>
          <description>Successful delivery and deployment of the assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final inscaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.
Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only.</description>
          <population>Intent to treat set (ITT). Four subjects (1 in the Absorb BVS arm and 3 in the XIENCE V arm) were excluded from the data analysis for acute success.
During the index procedure, 5 subjects withdrew consent following randomization and before any device attempts,3 in the Absorb BVS arm and 2 in the XIENCE V arm were excluded from all data analyses.</population>
          <units>Percentage of target lesions</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0"/>
                    <measurement group_id="O2" value="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Procedural Success</title>
        <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days). In dual target lesion setting, both lesions must meet clinical procedure success criteria to have a patient level procedure success.
Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population (PTE) analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only.</description>
        <time_frame>At time of procedure up to 7 days in hospital</time_frame>
        <population>ITT set. Four subjects (Absorb BVS (1) arm and XIENCE V arm (3)) were excluded from the data analysis for acute success. During the index procedure, 5 subjects withdrew consent following randomization and before any device attempts. Data from these 5 subjects (3 in the Absorb BVS arm and 2 in the XIENCE V arm) were excluded from all data analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Procedural Success</title>
          <description>Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days). In dual target lesion setting, both lesions must meet clinical procedure success criteria to have a patient level procedure success.
Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population (PTE) analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only.</description>
          <population>ITT set. Four subjects (Absorb BVS (1) arm and XIENCE V arm (3)) were excluded from the data analysis for acute success. During the index procedure, 5 subjects withdrew consent following randomization and before any device attempts. Data from these 5 subjects (3 in the Absorb BVS arm and 2 in the XIENCE V arm) were excluded from all data analyses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>0 to 37days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death (Cardiac, Vascular, Non-cardiovascular)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Myocardial Infarction</title>
          <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>MI was categorized as Q-wave MI (QMI) and non-Q-wave MI (NQMI) and also MI attributable to target vessel (TV-MI) and MI not attributable to target vessel (NTV-MI). In addition, MIs were adjudicated based on three different MI definitions (per-protocol, modified ARC and WHO definitions) with the per-protocol analysis being the primary analysis for the study.</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Lesion Revascularization (TLR)</title>
          <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Ischemia-driven TLR (ID-TLR)
Not ischemia-driven TLR (NID-TLR)</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Revascularization (TVR)</title>
          <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Ischemia-driven TVR (ID-TVR)
Not ischemia-driven TVR (NID-TVR)</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
        <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
          <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
        <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
        <time_frame>0 to 37days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
          <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
        <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
        <time_frame>0 to 208 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
          <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
        <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
        <time_frame>0 to 298 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
          <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
        <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
        <time_frame>0 to 393 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization (PCI and CABG)</title>
          <description>Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (PCI and CABG)</title>
        <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (PCI and CABG)</title>
        <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (PCI and CABG)</title>
        <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Coronary Revascularization (PCI and CABG)</title>
        <description>percutaneous coronary intervention (PCI) coronary artery bypass graft (CABG)</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death/All MI</title>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death/All MI</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death/All MI</title>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death/All MI</title>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Death/All MI</title>
        <time_frame>0 to 393 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Death/All MI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death/All MI</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death/All MI</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death/All MI</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death/All MI</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI</title>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI</title>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI</title>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI</title>
        <time_frame>0 to 393 Days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing All Death/All MI/All Revascularization (DMR)</title>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
          <population>Per-Treatment-Evaluable Population set (PTE)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
          <population>Per-Treatment-Evaluable Population set (PTE)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
          <population>Per-Treatment-Evaluable Population set (PTE)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>0 to 393 Days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
          <population>Per-Treatment-Evaluable Population set (PTE).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR [Target Lesion Failure (TLF)]</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>≤ 7 days post index procedure (In-hospital)</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR [Target Vessel Failure (TVF)]</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>≤ 7 days post index procedure (In-hospital )</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 208 days</time_frame>
        <population>Per-Treatment-Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Per-Treatment-Evaluable Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 298 days</time_frame>
        <population>Per-Treatment-Evaluable Population set (PTE)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and Ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Per-Treatment-Evaluable Population set (PTE)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
        <time_frame>0 to 393 days</time_frame>
        <population>Per-Treatment-Evaluable (PTE) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).</description>
          <population>Per-Treatment-Evaluable (PTE) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Event [MACE])</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Stent/Scaffold Thrombosis (Per Academic Research Consortium (ARC) Definition)</title>
        <time_frame>&lt; or = 1 day</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Stent/Scaffold Thrombosis (Per Academic Research Consortium (ARC) Definition)</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Subacute Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <time_frame>&gt;1 to 30 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subacute Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <time_frame>31 to 365 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Stent/Scaffold Thrombosis (Per ARC Definition)</title>
        <time_frame>0 to 365 days</time_frame>
        <population>Per-Treatment-Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Stent/Scaffold Thrombosis (Per ARC Definition)</title>
          <population>Per-Treatment-Evaluable Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Segment Minimum Lumen Diameter (MLD)</title>
        <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.
INSEGMENT: Within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Segment Minimum Lumen Diameter (MLD)</title>
          <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.
INSEGMENT: Within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.47"/>
                    <measurement group_id="O2" value="2.17" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Device Minimum Lumen Diameter (MLD)</title>
        <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Device Minimum Lumen Diameter (MLD)</title>
          <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.48"/>
                    <measurement group_id="O2" value="2.50" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Minimum Lumen Diameter (MLD)</title>
        <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population (PTE) Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Minimum Lumen Diameter (MLD)</title>
          <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
          <population>Per-Treatment-Evaluable Population (PTE) Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="0.48"/>
                    <measurement group_id="O2" value="2.68" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Minimum Lumen Diameter (MLD)</title>
        <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Distal Minimum Lumen Diameter (MLD)</title>
          <description>Minimum lumen diameter is defined as the shortest diameter through the center point of the lumen. Data are collected from two projections.</description>
          <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.45"/>
                    <measurement group_id="O2" value="2.37" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Segment Percent Diameter Stenosis (%DS)</title>
        <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Segment Percent Diameter Stenosis (%DS)</title>
          <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA). Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.02" spread="13.23"/>
                    <measurement group_id="O2" value="22.96" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Device Percent Diameter Stenosis (%DS)</title>
        <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Device Percent Diameter Stenosis (%DS)</title>
          <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
          <population>PTE population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.16" spread="14.36"/>
                    <measurement group_id="O2" value="11.15" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Percent Diameter Stenosis (%DS)</title>
        <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Percent Diameter Stenosis (%DS)</title>
          <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
          <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.09" spread="10.13"/>
                    <measurement group_id="O2" value="12.12" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Percent Diameter Stenosis (%DS)</title>
        <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Distal Percent Diameter Stenosis (%DS)</title>
          <description>The Percent Diameter Stenosis value calculated as 100 * (1 MLD/Reference vessel diameter (RVD)) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).
Reference vessel diameter based on QCA is derived from either the user defined method using average diameter of proximal and distal healthy segments or the interpolated method.</description>
          <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percent Diameter stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" spread="8.15"/>
                    <measurement group_id="O2" value="8.14" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Segment Angiographic Binary Restenosis (ABR)</title>
        <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%. InSegment is defined as within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Segment Angiographic Binary Restenosis (ABR)</title>
          <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%. InSegment is defined as within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Device Angiographic Binary Restenosis (ABR)</title>
        <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Device Angiographic Binary Restenosis (ABR)</title>
          <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Angiographic Binary Restenosis (ABR)</title>
        <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Angiographic Binary Restenosis (ABR)</title>
          <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
          <population>PTE population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Angiographic Binary Restenosis (ABR)</title>
        <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Distal Angiographic Binary Restenosis (ABR)</title>
          <description>Angiographic Binary Restenosis (ABR): Renarrowing of the artery defined as %DS ≥ 50%.</description>
          <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Segment Late Loss (LL)</title>
        <description>In-segment Late Loss is calculated as (in-segment MLD post-procedure) - (in-segment MLD at followup).</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Segment Late Loss (LL)</title>
          <description>In-segment Late Loss is calculated as (in-segment MLD post-procedure) - (in-segment MLD at followup).</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.40"/>
                    <measurement group_id="O2" value="0.13" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-Device Late Loss (LL)</title>
        <description>In-device late loss is calculated as (in-device MLD post-procedure) - (in-device MLD at followup).</description>
        <time_frame>At 1 year</time_frame>
        <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>In-Device Late Loss (LL)</title>
          <description>In-device late loss is calculated as (in-device MLD post-procedure) - (in-device MLD at followup).</description>
          <population>Per-Treatment-Evaluable Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.39"/>
                    <measurement group_id="O2" value="0.10" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proximal Late Loss (LL)</title>
        <description>Proximal Late Loss: Proximal MLD post procedure - Proximal MLD at followup.
Proximal is defined as within 5 mm of healthy tissue proximal to the device placement.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Proximal Late Loss (LL)</title>
          <description>Proximal Late Loss: Proximal MLD post procedure - Proximal MLD at followup.
Proximal is defined as within 5 mm of healthy tissue proximal to the device placement.</description>
          <population>PTE Population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.39"/>
                    <measurement group_id="O2" value="0.13" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal Late Loss (LL)</title>
        <description>Distal Late Loss calculated as Distal MLD post procedure - Distal MLD at followup.
Distal is defined as within 5 mm of healthy tissue distal to the device placement.</description>
        <time_frame>At 1 year</time_frame>
        <population>PTE population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb BVS System</title>
            <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
          </group>
          <group group_id="O2">
            <title>XIENCE V EECSS</title>
            <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
          </group>
        </group_list>
        <measure>
          <title>Distal Late Loss (LL)</title>
          <description>Distal Late Loss calculated as Distal MLD post procedure - Distal MLD at followup.
Distal is defined as within 5 mm of healthy tissue distal to the device placement.</description>
          <population>PTE population. Analysis population exclude subjects who are truly lost-to-follow-up.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Target lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.31"/>
                    <measurement group_id="O2" value="0.03" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>ITT population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Absorb BVS System</title>
          <description>Absorb BVS System: Subjects receiving Absorb BVS System</description>
        </group>
        <group group_id="E2">
          <title>XIENCE V EECSS</title>
          <description>XIENCE V EECSS: Subjects receiving XIENCE V</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary heart disease aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Non ST-elevation myocardial infarction (STEMI)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest distressed feeling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest pain (noncardiac)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Drug resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Common bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gallstones</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Community acquired pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Electric injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Knee injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Postoperative hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Type II diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteral calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Leukocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Coronary heart disease aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Effort angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Non STEMI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Stable angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Unstable angina</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Black stools</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Mouth bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Tooth socket bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Catheter site bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest distressed feeling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Chest pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Drug resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Drug side effect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Feeling of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Common bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gallstones</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Community acquired pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Electric injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Knee injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Post procedural vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Postoperative hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Creatine kinase MB increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Creatine kinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Type II diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Type II diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Numbness in hand</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Ureteral calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Dyspnea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Nasal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Paroxysmal cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Short of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="239"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karine Piard-Ruster, Principal Scientist Clinical Research</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>+1 408-845-0764</phone>
      <email>karine.piard-ruster@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

